Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is conducting a Phase 1 clinical trial titled ‘AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES.’ The study aims to assess the safety and effects of PF-08046037, alone or combined with sasanlimab, in patients with advanced or metastatic cancers such as non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, or pancreatic ductal adenocarcinoma. This trial is significant as it explores potential new treatments for these challenging conditions.
The interventions being tested include PF-08046037, administered intravenously, and sasanlimab, given subcutaneously. These treatments are designed to target and manage advanced malignancies, potentially offering new therapeutic options for patients.
The study follows an interventional design with a non-randomized, sequential intervention model focusing on dose escalation and expansion. There is no masking involved, and the primary purpose is treatment, aiming to optimize and expand the dosage of the drugs being tested.
The study began on May 6, 2025, with the latest update submitted on July 8, 2025. These dates are crucial as they indicate the study’s current status and progression, which is still in the recruiting phase.
The market implications of this study could be significant for Pfizer’s stock performance, as successful outcomes may enhance investor confidence and position Pfizer favorably against competitors in the oncology market. The ongoing research into advanced cancer treatments remains a critical area of interest for investors.
The study is ongoing, with further details available on the ClinicalTrials portal.